Ruto Pushes Kenya as Africa’s Pharmaceutical Manufacturing Hub

By Pa Modou Cham

William Samoei Ruto, President of Kenya has unveiled an ambitious plan to position Kenya as a leading pharmaceutical manufacturing and health innovation hub for Africa, calling for stronger continental cooperation to unlock the continent’s industrial potential.

Speaking at the Africa Initiative for Medical Access and Manufacturing (AIM2030) meeting ahead of the Africa Forward Summit in Nairobi, President Ruto said his government is taking “deliberate steps” to strengthen the country’s pharmaceutical ecosystem and attract greater confidence in locally manufactured medical products.

Central to the plan is the enhancement of Kenya’s National Regulatory Authority to achieve the World Health Organisation’s Maturity Level 3 status — a globally recognised benchmark for regulatory systems that ensure the quality, safety and efficacy of medicines and health products.

Ruto said attaining the WHO standard would reinforce international confidence in Kenyan-made pharmaceutical products while accelerating the country’s emergence as a regional centre for medical manufacturing, innovation and supply chains.

“Our goal is to position Kenya as a regional hub for pharmaceutical manufacturing, health innovation, and medical supply chains serving both the Kenyan and wider African markets,” the Kenyan leader declared.

The President highlighted Kenya’s strategic geographic location as the gateway to Eastern Africa’s rapidly expanding economic bloc, noting that the country’s growing domestic market, modern logistics infrastructure and favourable investment climate place it in a strong position to lead Africa’s pharmaceutical transformation.

Ruto also urged African governments to move beyond rhetoric and fully implement commitments on regulatory harmonisation, market integration and industrial policy to unlock the continent’s manufacturing capabilities.

The remarks come amid increasing calls for Africa to reduce dependence on imported medicines and strengthen local production following supply chain disruptions experienced during the COVID-19 pandemic.

Analysts say Kenya’s push could significantly reshape pharmaceutical production in East Africa, boost regional access to medicines and create new opportunities for investment and employment across the health sector.